Fennec Pharmaceuticals Inc. (FENC), Friday announced that the National Institute for Health and Care Excellence or NICE has recommended Pedmarqsi, intended for the prevention of Cisplatin-induced hearing loss in patients with localized, non-metastatic, solid tumors.
The pharmaceutical company added that the findings from two open-label, randomized Phase 3 trials, SIOPEL 6 and the Clinical Oncology Group Protocol ACCL0431 demonstrated around 50 percent reduction in the occurrence of cisplatin-induced hearing loss in patients treated with cisplatin and sodium thiosulfate.
For comments and feedback: editorial@rttnews.com